Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years
Gene therapy sustains bleeding control in haemophilia A trial europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood
Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec